Form D · Pharmaceuticals
Follica, Inc
Mendham, NJ · CIK 0001423344
Offering snapshot reported Nov 8, 2010 · SEC filing
- Reported sold
- $135K Offering amount: $135K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 25, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 8, 2010 | Initial | $134,999 | No comparison | 1 | SEC filing |
| Sep 10, 2010 | Amendment | $7,607,101 | $107,102vs Jun 1, 2010 | 7 | SEC filing |
| Jun 1, 2010 | Initial | $7,499,999 | No comparison | 5 | SEC filing |
| Aug 26, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 7, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-150183
Source: Form D, filed Nov 8, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin Bitterman | Director |
| Christopher Ehrlich | Director |
| William Ju | Director, Executive |
| Kirk Raab | Director |
| Daphne Zohar | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
88 East Main Street Suite H 501
Mendham, NJ, 07945
Mendham, NJ, 07945